Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) said Thursday that a major Canadian pharmacy chain will dispense its ketamine topical treatment at one of its locations.
The move strengthens Champignon’s vertically integrated psychedelic medicine offering by accelerating its ketamine topicals fulfillment capabilities, the firm said in a statement.
Vancouver-based Champignon will also leverage the pharmacy’s infrastructure to distribute ketamine topical prescriptions to a network of medical, pain and addiction clinics in Canada, broadening the company’s revenue stream.
READ: Champignon Brands inks blockbuster deal to roll out network of psychedelic medicine clinics in North America
The clinics will use Champignon’s formulations to conduct chart reviews and patient studies under human ethics approval from Health Canada and data from the studies will be used to published peer-reviewed mandates and expedite future human clinical trials planned for later this year.
Additionally, Champignon and the pharmacy will design a Level B clean room located at the pharmacy to compound and package the company’s ketamine formulations, which include off-market intranasal esketamine and ketamine topicals. The clean room is anticipated to be completed by 3Q 2020 and will be designed in line with national pharmacy regulatory guidelines.
“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies,” CEO Gareth Birdsall said in the statement.
“From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle,” he added.
Champignon’s central fill capabilities optimizes the company’s prescription fulfilment infrastructure and advance its ketamine data collation initiatives for conditions like concussions and traumatic brain injury, anxiety and treatment-resistant depression.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas